Author

Steven J. Richards

Observed name: Steven Richards

Institution: Exelixis (United States)

Observed institutions: Exelixis (United States), Abbott (United States)

OpenAlex ID: A5055845908

Discovery of XL413, a potent and selective CDC7 inhibitor

2012 · Elena S. Koltun, Amy Lew Tsuhako, et al. · Bioorganic & Medicinal Chemistry Letters · 88

Discovery of 2-[4-{{2-(2S,5R)-2-Cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic Acid (ABT-279): A Very Potent, Selective, Effective, and Well-Tolerated Inhibitor of Dipeptidyl Peptidase-IV, Useful for the Treatment of Diabetes

2006 · David J. Madar, Hana Kopecka, et al. · Journal of Medicinal Chemistry · 37

Discovery and Characterization of an Inhibitor of Glucosylceramide Synthase

2012 · Steven Richards, Christopher J. Larson, et al. · Journal of Medicinal Chemistry · 21

Discovery of potent and selective inhibitors of 11β-HSD1 for the treatment of metabolic syndrome

2006 · Steven Richards, Bryan Sorensen, et al. · Bioorganic & Medicinal Chemistry Letters · 21

Discovery of a new class of glucosylceramide synthase inhibitors

2011 · Elena Koltun, Steven Richards, et al. · Bioorganic & Medicinal Chemistry Letters · 15

Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists

2006 · Steven J. Richards, Thomas W. von Geldern, et al. · Bioorganic & Medicinal Chemistry Letters · 10

Erratum to “Discovery of XL413, a potent and selective CDC7 inhibitor” [Bioorg. Med. Chem. Lett. 22 (2012) 3727–3731]

2012 · Elena S. Koltun, Amy Lew Tsuhako, et al. · Bioorganic & Medicinal Chemistry Letters · 7

Thiazolidinedione‐Based Insulin Sensitizers:PPAR‐γ Agonists for the Treatment of Type 2 Diabetes

2012 · Steven Richards · Wiley eBooks

ChemInform Abstract: Discovery of a New Class of Glucosylceramide Synthase Inhibitors.

2012 · Steven Richards, et al. et al. · ChemInform

Works count: 9

Citation count: 199

H-index: 7

I10-index: 6